Camrelizumab-associated MG-like ocular neuromuscular toxicity after PD-1 inhibitor rechallenge in metastatic hepatocellular carcinoma: a case report with serial muscle injury-related biomarker changes.

AiRuiKa (camrelizumab) - Elevar Therapeutics

http://www.ncbi.nlm.nih.gov/pubmed/42620508

Hui Jiang; Jie Li; Kesheng Bo; Lusheng Wang; Mengdie Chen; Ming Chen

Aug 21, 2026